Invivyd (IVVD) EPS (Weighted Average and Diluted) (2021 - 2025)
Invivyd (IVVD) reported EPS (Weighted Average and Diluted) of -$0.07 for Q4 2025, up 51.4% on a YoY basis from -$0.05 in Q4 2024, and down 21.51% quarter-over-quarter from -$0.06 in Q3 2025.
Invivyd (IVVD) EPS (Weighted Average and Diluted) (2021 - 2025) Analysis & Trends
Invivyd has reported EPS (Weighted Average and Diluted) for 5 years, with the latest figure at -$0.07 in Q4 2025.
- For the quarter ending Q4 2025, EPS (Weighted Average and Diluted) rose 51.4% year-over-year to -$0.07; the trailing twelve-month figure through Dec 2025 stood at -$0.32 (up 77.78% YoY), and the FY2025 full-year result was -$0.3, up 79.02% from the prior year.
- EPS (Weighted Average and Diluted) for Q4 2025 stood at -$0.07, down from -$0.06 in the prior quarter.
- The five-year high for EPS (Weighted Average and Diluted) was $1.74 in Q4 2021, with the low at -$178.86 in Q2 2021.
- Historically, EPS (Weighted Average and Diluted) has averaged -$9.68 across 5 years, with a median of -$0.4 in 2024.
- The largest YoY upside for EPS (Weighted Average and Diluted) was 99.74% in 2022 against a maximum downside of 123.56% in 2022.
- Invivyd's EPS (Weighted Average and Diluted) stood at $1.74 in 2021, then plunged by 123.56% to -$0.41 in 2022, then tumbled by 63.41% to -$0.67 in 2023, then soared by 77.61% to -$0.15 in 2024, then surged by 51.4% to -$0.07 in 2025.
- The last three EPS (Weighted Average and Diluted) figures came in at -$0.07 (Q4 2025), -$0.06 (Q3 2025), and -$0.12 (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Weighted Avg. Diluted) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | 0.68 |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 3.06 |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 3,086.42 |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 0.00 |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 0.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 4.02 |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -0.61 |
| 10 | Invivyd | 168.41 Mn | -58.28 Mn | - | -0.07 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -0.07 |
| Sep 30, 2025 | -0.06 |
| Jun 30, 2025 | -0.12 |
| Mar 31, 2025 | -0.14 |
| Dec 31, 2024 | -0.15 |
| Sep 30, 2024 | -0.51 |
| Jun 30, 2024 | -0.40 |
| Mar 31, 2024 | -0.38 |
| Dec 31, 2023 | -0.67 |
| Sep 30, 2023 | -0.36 |
| Jun 30, 2023 | -0.46 |
| Mar 31, 2023 | -0.32 |
| Dec 31, 2022 | -0.41 |
| Sep 30, 2022 | -0.42 |
| Jun 30, 2022 | -0.47 |
| Mar 31, 2022 | -0.93 |
| Dec 31, 2021 | 1.74 |
| Sep 30, 2021 | -0.98 |
| Jun 30, 2021 | -178.86 |